While the ATEMPT trial supports the use of T-DM1 as a potential adjuvant systemic therapy in stage I HER2 + breast cancers, it remains unclear which patients stand to benefit from this de-escalation5. The gene discussed is ERBB2; the disease is breast carcinoma.